Review Article
Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
Doreen Grzelak, NP-C, AOCN®, AGN-BC
From Virginia Cancer Specialists, Fairfax, Virginia
Author’s disclosure of conflicts of interest is found at the end of this article.
Correspondence to: Doreen Grzelak, NP-C, AOCN®, AGN-BC, 8613 Lee Highway, Fairfax, VA 22031. E-mail: grzelakdoreen@gmail.com
J Adv Pract Oncol 2021;12(5):488–491 |
https://doi.org/10.6004/jadpro.2021.12.5.4 |
© 2021 Harborside™
ABSTRACT
Pancreatic cancer is the fourth leading cause of death from cancer in both men and women. Pancreatic cancer is typically diagnosed at an advanced stage and has an overall 5-year survival of approximately 9.3%. The National Comprehensive Cancer Network recommends both germline testing (testing cells such as blood or skin that do not have cancer) as well as somatic testing (testing cells with cancer) for pathogenic variants that may increase the risk of pancreatic cancer. In December 2019, the U.S. Food & Drug Administration approved the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib for maintenance treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma in individuals who have completed at least 16 weeks of progression-free treatment with first-line platinum-based chemotherapy. This new therapy option has implications not only for treatment but also for the role of the oncology advanced practitioner as genetic testing becomes more prevalent in the care of patients with cancer.
For access to the full length article, please
sign in.
